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nostic modalities in the acute stem cell transplant period. A normal
CXR does not deﬁnitively exclude a pulmonary process in this
group of patients and additional CT evaluation should be consid-
ered, particularly in patients with pulmonary symptoms.
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HUMAN POLYOMAVIRUS BK AND JC INFECTION IN CHILDREN AFTER
HEMATOPOIETIC STEM CELL TRANSPLANTATION: ANALYSIS OF RISK
FACTORS CONTRIBUTING TO VIRUSES REACTIVATION AND HEMOR-
RHAGIC CYSTITIS
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Polyomaviruses (HPV: BKV or JCV)–induced late-onset hem-
orrhagic cystitis (HC) is a signiﬁcant cause of morbidity after
hematopoietic stem cell transplantation (HSCT). However, issues
facilitating HPV reactivation and related HC remain unclear. The
aim of the study was to evaluate the incidence, risk factors and
clinical implications of BKV and JCV infection in children after
HSCT. One hundred forty two children (121 after allo- and 21
after auto-HSCT) were prospectively evaluated for BKV/JCV in-
fection and HC. Viral DNA was identiﬁed in plasma and urine
with qualitative PCR. The PCR products were cleft with the
enzyme BamH1 to discriminate between BKV and JCV sequences.
HC diagnosis was based on the clinical symptoms, the presence of
hematuria and USG of the bladder. Cumulative incidence (CI)
curves were created to assess the risk of BKV or JCV infection.
Multivariate analysis of potential risk factors of HPV reactivation
and HC among allografted patients (Age, gender, diagnosis, donor,
cell source, CMV reactivation, conditioning, GvHD and its pro-
phylaxis) was performed with Fine and Grey model. RESULTS:
HPV viruria was detected in 6 (28.5%) of 21 autografted patients,
in 5 BKV (23.8%) and 1 JCV (4.8%), only 1 patient developed HC.
No HPV viremia was observed. Following allo-HSCT, HPV were
found in 65 (53,7%) children. BKV viruria was detected in 60
(49,5%) and was accompanied by BKV viremia in 15 patients. JCV
viruria was discovered in 4 (3.3%) children with concomitant JCV
viremia in 1 patient. In 1 child (0.8%) parallel BKV and JCV
viremia and viruria were found. The CI of HPV viruria was higher
among children after allo-HSCT, however the difference was in-
signiﬁcant (p0.07). In univariate analysis, the following signiﬁ-
cant risk factors of HPV viruria were identiﬁed: age 10 years,
HSCT from MUD and ATG in the conditioning. In multivariate
analysis age remained the only signiﬁcant. Multivariate analysis of
potential risk factors of HC in children with HPV viruria revealed
that HPV viremia and chemotherapy-based conditioning increased
the risk signiﬁcantly, while TBI appeared to do the opposite.
CONCLUSIONS: BKV viruria is common in children after allo-
HSCT. The risk of HPV shedding increases with age and this
indirectly indicates reactivation rather than de novo infection. HC
after allo-HSCT is induced by HPV in conjunction with viremia
and chemotherapy-based conditioning. However, the role of addi-
tional factors can not be excluded.
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THERAPEUTIC MONITORING OF SIROLIMUS IS ESSENTIAL IN PEDIAT-
RIC BMT RECIPIENTS
Goyal, R.K.1,2, Venkataramanan, R.3,2, Krasowski, M.4, Sindhi, R.3,2,
Zorich, G.P.1, Grupp, S.5, Wall, D.6, Bunin, N.5, Pulsipher, M.A.7
1Children’s Hospital of Pittsburgh, Pittsburgh, PA; 2University of Pitts-
burgh, Pittsburgh, PA; 3Thomas E Starzl Transplantation Institute,
Pittsburgh, PA; 4UPMC Pathology, Pittsburgh, PA; 5Children’s Hos-
pital of Philadelphia, Philadelphia, PA; 6Texas Transplant Institute, San
Antonio, TX; 7University of Utah School of Medicine, Salt Lake City,
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Limited data on sirolimus (SRL) in adult BMT patients is con-
sistent with a long elimination half-life (t1/2; 57-63 h) and little
effect of an occasional missed dose on overall drug exposure.
Pharmacokinetic (PK) studies in pediatric organ transplant recip-
ients suggest that SRL may be metabolized more rapidly in chil-
dren. BMT patients may have variable SRL exposure due to gas-
trointestinal toxicity, and interactions with calcineurin inhibitors
and imidazole antifungaldrugs.
SRL PK proﬁles were evaluated in 19 pediatric BMT recipients
with high-risk ALL treated on a pilot trial using SRL-based
GVHD prophylaxis. Mean age at transplant was 11 y (4-21 y); 13
males, 6 females; 14 Whites, 4 Hispanic, 1 Black. Stem cell source:
12 unrelated cord blood, 6 sibling bone marrow, and 1 unrelated
PBSC. Preparative regimen: TBI 1200 cGy, thiotepa 10mg/kg,
and cyclophosphamide 120mg/kg. GVHD prophylaxis: continuous
infusion tacrolimus from day -2, IV methotrexate (5mg/m2, 4-5
doses) and oral SRL (2.5 mg/m2/d; 4mg/d max) from day -2 (1),
day -1 (1), day 0 (16), and day 1 (1). Out of 119 SRL doses, 14 were
followed by emesis, and 10 of these were redosed. Sixteen patients
also received ﬂuconazole prophylaxis.
Timed multiple blood samples (8-9) were drawn after sixth (14),
seventh (5), or eighth (1) dose of SRL. Whole blood SRL concen-
trations were measured by liquid chromatography with tandem-
mass spectrometry. Mean SRL dose was 2.6 mg/day (1-4 ); 2.3
mg/day/m2 (1.1-4). In 20 PK studies, SRL concentrations normal-
ized to dose (mean	SD, ng/mL/mg) were: trough level before the
dose (C0) 3.50	2.40, maximum (Cmax) 6.74	5.37, and 24 hours
later (C24) 3.29	2.38. C0 and C24 were similar and correlated well
(r2  0.905), indicating achievement of steady state. SRL dose did
not correlate with AUC (r2  0.12), while C0 and C24 correlated
well with AUC (r2 0.918; 0.929, respectively). SRL apparent oral
clearance was 4.1	4.5 ml/min/kg (0.87–20) and t1/2 25	13 h (9-71
h). SRL t1/2 in our patient group were markedly lower than those
reported in adults, and comparable to those observed in pediatric
liver and small bowel transplant recipients on tacrolimus and SRL
(19.3 to 21.2 h). In conclusion, we show that GVHD prophylaxis
with SRL is feasible even in young children, and PK data supports
24 h dosing interval; wide individual variability and lack of corre-
lation of dose with AUC supports the need for SRL therapeutic
monitoring and dose adjustments based on steady state blood
levels.
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SYNDROME (SOS) FOLLOWING HEMATOPOIETIC STEM CELL TRANS-
PLANT IN PEDIATRIC PATIENTS
Hill, A.B.1, Robertson, K.A.1, Gowan, D.J.1, Lorch, C.1,
Collura, J.M.1, Renbarger, J.1, Goebel, W.S.1, Haut, P.P.1 1Indiana
University/Riley Hospital for Children, Indianapolis, IN.
Sinusoidal Obstruction Syndrome (SOS) is characterized by en-
dothelial cell damage in the liver and associated with signiﬁcant
morbidity and mortality. It is a well documented complication of
abdominal irradiation, speciﬁc chemotherapeutic agents, monoclo-
nal antibodies and hematopoietic stem cell transplant (HSCT).
Deﬁbrotide is an experimental polydeoxyribonucleotide agent with
liver endothelial cell activity that has clinically encouraging results
in the treatment of SOS. In this study, we report a single institution
retrospective analysis of the efﬁcacy of deﬁbrotide in treating SOS
in a post-HSCT pediatric population. A total of 11 patients were
treated with deﬁbrotide after being clinically diagnosed with severe
SOS having a 30% likelihood of mortality based on the Bearman
model of life expectancy. The protocol was IRB approved and each
patient was individually assigned an FDA IND number prior to
treatment. All patients had received ursodiol for SOS prophylaxis.
Seven of 11 patients received TBI-based conditioning and 4 pa-
tients received ablative chemotherapy alone. The median age was
6.6 years at time of treatment (range, 5 months to 18 yrs). All
patients were Caucasian, with 4 males and 7 females. The stem cell
source was unrelated cord blood in 4 patients, unrelated bone
marrow in 2, autologous peripheral blood in 2, and related bone
marrow in 3. Engraftment (ANC 500) occurred on average 23.2
days post-SCT (mean: Cord  30 days, BM  22.6 days, autolo-
gous  11 days). 10 of 11 patients had primary malignancies
(AML, ALL, neuroblastoma, pineoblastoma) while 1 patient had
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Wolman’s Syndrome. SOS was clinically diagnosed and treatment
began between 7 and 37 days post-HSCT (mean17 days). Pa-
tients were treated per protocol with a starting dose of 10 mg/kg/
day with subsequent increases of 10 mg/kg/day until clinically
therapeutic to a max of 60 mg/kg/day (exception:  2 y/o popu-
lation allowed a maximum of 100 mg/kg/day, n1). The duration
of deﬁbrotide treatment ranged from 13 to 31 days (mean18
days).There were no signiﬁcant complications related to the deﬁ-
brotide infusions or therapy. Seven of 11 (63.6%) patients showed
complete response to the therapy, while 4 patients were classiﬁed
as non-responders. The 100 day post-HSCT survival rate was
54.5% (6/11) for all patients. In conclusion, this study provides
further evidence that deﬁbrotide is an efﬁcacious and safe treat-
ment for pediatric SOS occurring after HSCT.
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CIFIC RECEPTORS; EFFECTS IN PATIENTS WITH NEUROBLASTOMA
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Long-term survival for children with neuroblastoma remains
poor despite intensiﬁcation of therapy. Neuroblastoma cells ex-
press a number of potential target antigens for the immune re-
sponse including GD2 and T cells engineered to express chimeric
antigen receptors (CAR) for these antigens might supplement
conventional therapeutics. Unfortunately, modiﬁcation of primary
T cells with CAR has demonstrated limited functionality and
persistence in vivo, likely because the target tumor cells lack the
co-stimulatory molecules required for T cell activation. We have
previously shown that Epstein Barr Virus speciﬁc cytotoxic T
lymphocytes (EBV-CTLs) persist and function in vivo long term,
in part because they receive co-stimulation from EBV infected B
lymphocytes. We reasoned that EBV-CTLs engineered to express
GD2-CAR would also receive such co-stimulatory signals follow-
ing engagement of their native (EBV-speciﬁc) receptors, and hence
would persist longer than primary T cells expressing the same
CAR. We therefore developed a Phase I clinical study to directly
compare EBV CTL-CAR and T-cell CAR. We used two retroviral
vectors distinguishable by a non-expressed marker sequence so that
signal detected in vivo could be assigned to the CTL or the T cells.
Vector use was alternated between the two cell populations. To
date 3 patients received 210E7/m2 of each cell population, while
4 have received 110E8/m2 of each product. We observed no
adverse effects. Even at the low cell doses used to date, signal could
be detected for 6 weeks in peripheral blood. Differential quantita-
tive PCR analysis of the signal showed that EBV-CTL CAR were
present at a higher level and persisted longer than primary T cell
associated CAR. Clinically there has been one mixed response and
two with stable disease, while one patient treated in CR remains
disease free at 12 months. 4 patients have died of progressive
disease. Expressing chimeric antigen receptors in virus speciﬁc T
cells appears to improve lymphocyte survival after adoptive transfer
compared to CAR expression in primary T cells, and may thereby
increase the therapeutic potential of these cells. It will be of interest
to use this approach early after stem cell transplantation, when
residual malignant cells are at their lowest level, and homeostatic
signals will favor expansion of adoptively transferred engineered
CTL.
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EFFECTIVE IMMUNOTHERAPY FOR NEUROBLASTOMA REQUIRES HSCT
AND T CELL TRANSFER
Orentas, R.J.1,2, Jing, W.1,2, Yan, X.1,2, Johnson, B.D.1,2 1Medical
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We have employed a mouse model for neuroblastoma, AGN2a
cells injected subcutaneously in to strain A/J mice, to demon-
strate that transfection of AGN2a with CD80, CD86, CD54,
and CD137L transforms this lethal cell line in to an effective
cell-based vaccine (AGN2a-4P). When tumor vaccines are ad-
ministered in the context of Treg blockade (with anti-CD25
antibody), the anti-tumor effect is heightened. Our previous
work also demonstrated that the inclusion of CD137L in the
vaccine preparation is uniquely responsible for a strong anti-
tumor T cell response. However, when we switched from tu-
mor-challenge to tumor-bearing regimens the vaccine was in-
effective. Even the inclusion of gene expression vectors
encoding GM-CSF, IL-15, lymphotactin, or SLC did not in-
hibit tumor progression. In order to determine if any impact
could be made in tumor-bearing animals, we initiated a tumor-
bearing model system featuring HSCT. Analysis of lymphoid
reconstitution post-HSCT revealed that up to day 21, mice
remained severely lymphopenic. However, it was during this
time period that vaccination with AGN2a-4P proved most ef-
fective in a tumor-challenge experiment. Moreover, vaccination
early post-HSCT was markedly improved when T cells were
adoptively transferred 3 days after HSCT, just prior to the
initiation of AGN2a-4P vaccination. ELISPOT data with puri-
ﬁed CD4 and CD8 cells indicated that adoptively transferred
lymphocytes early post-conditioning generated an IFN--pro-
ducing tumor-speciﬁc effector population. Furthermore, splenic
reconstitution studies at day 21 clearly indicated that animals
given lymphocyte adoptive transfer had greater percentages of
donor (as opposed to residual host) T cells in their spleens. This
indicates that combining adoptive T cell transfer with HSCT
alters the lymphocyte populations present early post-HSCT,
and that these populations are crucial to the generation of
anti-tumor effector cells. We then tested our post-HSCT vac-
cine strategy in a tumor-bearing model. 1 105 live tumor cells
were given on day -8, TBI on day -1, HSCT consisting of bone
marrow plus 6 106 T cells on day 0, and irradiated AGN2a-4P
vaccine on days 2 and 7. Effective neuroblastoma therapy re-
quired HSCT, T cell transfer and AGN2a-4P vaccination. Our
results support the current practice of autologous HSCT for
neuroblastoma therapy, and suggest that the addition of vacci-
nation and adoptive immunotherapy (T cell transfer) to these
regimens may improve outcomes.
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PEDIATRIC BLOOD AND MARROW TRANSPLANT CONSORTIUM STUDY
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Kadota, R.6, Wall, D.7, Grupp, S.8, Kletzel, M.9 1University of Utah/
Primary Children’s Medical Center, Salt Lake City, UT; 2Children’s
Hospital of Pittsburgh, Philadelphia, PA; 3Vanderbilt University Med-
ical Center, Nashville, TN; 4Children’s Hosp at Westmead, Sydney,
Australia; 5Children’s Healthcare of Atlanta, Atlanta, GA; 6Children’s
Hospital of San Diego, San Diego, CA; 7Methodist Children’s Hospital,
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The role of reduced intensity conditioning (RIC) regimens in
pediatric pts is unclear. To deﬁne the feasibility and toxicity of
this approach using multiple stem cell sources in pediatric pts
ineligible for myeloablative transplant, we conducted a trial at
25 centers participating in the Pediatric Blood and Marrow
Transplant Consortium (PBMTC). Thirty two pediatric pts
(age 2-20yrs, med 12) have been enrolled to date with the
following stem cell sources: 7 related donor (RD) BM (2 mis-
matched); 5 RD-PBSC; 9 unrelated donor (UD) BM; 4UD-
PBSC; 7 UD-CB. Qualifying indications included a previous
allogenic (n15) or autologous (n4) transplant, severe organ
toxicity (n5), invasive fungal infection (n2), and other co-
morbidities, (n 6 pts, 4 with Down syndrome). Diagnoses
included ALL (4 CR2; 9 CR3), AML (6 CR2; 3 CR3; 1 second-
ary), MLL (1 CR3), HD (2 CR3), B-NHL (1 PR3), MDS (2 RA;
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